Metrion extends stem cell collaboration with Axiogenesis

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/darnellvfx)
(Image: iStock/darnellvfx)

Related tags: Cardiac safety, Stem cell

Through their extended collaboration, Axiogenesis and Metrion Biosciences will further develop iPSC-derived cell based assays for drug discovery.

Per the agreement, Axiogenesis will share new iPS-derived cardiomyocytes and neurons with Metrion for profiling and validation on its screening platforms.

Additionally, Metrion will use commercial Axiogenesis cell products in its ion channel screening, cardiac safety, and translational phenotypic assays.

According to the companies, developing cardiac safety assays using iPS cardiomyocytes is important to the FDA’s Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative – an initiative in which both companies are participating.

The two companies are currently working together to validate cardiac ion channel assays. Dr. Marc Rogers, Chief Scientific Officer at Metrion Biosciences, commented that the new collaboration will enable the companies to prolong this work.

Specifically, he explained the companies will use iPS neurons for pain and other neuroscience therapies and “to create more predictive neurotoxicology assays that will enable the potential risk and side-effects of new compounds to be assessed more accurately and cost-effectively​.”

Growing interest for iPS cell profiling

Last month, Dr. Andrew Southan, the company's newly appointed head of commercial operations told us​ the company plans to form strategic alliances with other companies "where it gives us additional breadth without significantly increasing our costs.​" 

The company recently invested in new laboratories, equipment, and staff – including Southan – as part of the company's continued growth strategy.

Moving into the field of stem-cell derived iPS cells, specifically for cardiomyocytes for translational cardiac safety assay testing, is also part of this strategy.

Marc Rogers, Metrion’s CSO told us the company has received a lot of recent interest in its iPS cell profiling and cardiac assay validation services, as demonstrated by the extended collaboration with Axiogenesis announced today.

The company has also invested in new phenotypic platforms, such as multi-electrode arrays (MEA) and impedance platforms, which Rogers said will enable the design, validation and implementation of translational cardiac and neuronal assays using native tissue (e.g. dorsal root ganglion for pain, cortical neurons for CNS programmes) and iPS cells.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us


View more